Are ARID5B and IKZF1 polymorphisms also associated with childhood acute myeloblastic leukemia: the ESCALE study (SFCE)?
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Of the average 470 new cases of acute leukemia (AL) registered annually in France among children aged o15 years, 1 B90 are cases of acute myeloblastic leukemia (AML). Down's syndrome and other inheritable predisposing diseases explain only a small proportion of AML. Most childhood AML occurs before the age of 2 years, and researches have mainly focused on antenatal or early childhood exposures. 2 Advances in genetic technologies have enabled genome-wide association studies (GWAS) to be undertaken with the aim of identifying common single-nucleotide polymorphism variant alleles associated with small increases in AL risk. GWAS on acute lymphoblastic leukemia (ALL) have previously identified SNPs in ARID5B (rs7073837, rs10740055, rs7089424, rs10821936 and rs10994982) [3] [4] [5] [6] and IKZF1 (rs6964823, rs4132601, rs6944602 and rs11978267). [3] [4] [5] [6] In the present paper, the associations between childhood AML and the polymorphisms previously identified for ALL in ARID5B and IKZF1 were investigated in a candidate gene approach, using the data from the ESCALE case-control study.
The ESCALE study has been previously described in detail. 7, 8 Briefly, the cases were children o15 years old diagnosed with AL, lymphoma, central nervous system tumor or neuroblastoma in 2003-2004 and identified through the National Registry of Childhood Hematopoietic Malignancies. The study included 101 AML cases, 92% of the 110 eligible cases. A blood sample was obtained from 89 cases (88% of the included cases), 66 of whom were successfully genotyped. The ESCALE controls were randomly selected contemporaneously with the cases from French households with a landline telephone. Of the 2360 eligible controls identified, 1681 controls (71%) were included, 810 of whom provided buccal swab brushes, and 570 were successfully genotyped for candidate SNPs. The cases were genotyped on an Illumina 370K Quad BeadChip (San Diego, CA, USA) and the controls for 4868 candidate SNPs on Illumina Infinium iSelect custom beadchips (IntegraGen, Evry, France), including rs7073837, rs10740055 and rs7089424 in ARID5B, and rs6964823, rs4132601 and rs6944602 in IKZF1. Quality control excluded 109 ESCALE controls with an individual call rate o95% and 10 AML cases with individual call success o97%, low or high heterozygosity or discrepancies between stated sex and sexual chromosomes. Mean individual call rates were 99.9% for the cases and 98.5% for the controls. To control for potential population stratification bias, the analyses were restricted to the 51 cases and 442 controls who had at least two European-born grandparents. For the cases, the indicator predicted (with 98.2% sensitivity and 94.3% specificity) the CEPH classification, 'Caucasian derived', by principal component analysis, from 96 609 SNPs. It was assumed that having at least two European-born grandparents was an equally good proxy for the controls, for whom the SNPs were not available. The 51 AML cases of European descent consisted of 8 M1, 10 M2, 5 M3, 4 M4, 15 M5, 4 M7 and 5 unspecified AML.
The allelic dose of imputed SNPs was estimated and included as a continuous variable in the logistic models. Genotypic ORs were estimated using the homozygote common genotypes as references. Haplotypes were also inferred using the ExpectationMaximization algorithm implemented in PLINK, and posterior haplotype probabilities were used as weights in the logistic models. Table 1 presents the associations between AML and the candidate polymorphisms in IKZF1 and ARID5B. The allelic ORs for the associations between ARID5B SNPs and AML were greater than one, but the SNPs of ARID5B did not fit co-dominant models well: carrying the variant alleles of rs7073837 (A), rs10740055 (C) and rs7089424 (G) (dominant coding) was associated with odds ratio (OR) of 2.0 (1.0-4.0), 3.3 (1.3-8.6) and 1.9 (1.0-3.6), respectively, whereas the corresponding allelic ORs were equal to 1.2 (0.8-1.8), 1.3 (0.9-2.1) and 1.3 (0.9-2.1). AML was inversely related to carrying the variant allele of rs4132601 in IKZF1 (OR ¼ 0.5 (0.3-0.9)), on the contrary to what has been observed for ALL. [3] [4] [5] [6] The numbers were small, but none of the relationships seems to point specifically to any cytological subtype of AML (not shown). The associations were not modified after adjustment for parental professional category and for the environmental, immune or lifestyle factors associated with AML in the present study. [8] [9] [10] The study of the haplotypes, based on small numbers, suggested that the association with ARID5B mainly relied on rs10740055, reinforced with either none or both of the two other polymorphisms, and showed that the association with IKZF1 was driven by rs4132601 alone (Supplementary Table 1) .
Somatic deletion of IKZF1 is known to be associated with survival in childhood ALL. 11 In the present study, 1-and 5-year survival were similar between non-genotyped AML cases and genotyped AML cases, as well as between non-carriers and carriers of rs4132601 variant. Therefore, selection of surviving AML case is unlikely to explain our results.
A recent candidate gene study reported a significant association between infant AML and rs11978267 in IKZF1 (allelic OR equal to 1.8 (1.2-2.6)). 12 The authors did not investigate rs11978267 in IKZF1 and they reported no association between ARID5B SNPs and infant AML. The sample size of the present study did not allow restriction of the analysis to the children o1-year-old.
Accepted article preview online 27 August 2012; advance online publication, 11 September 2012 Letters to the Editor In conclusion, this study, although based on small numbers, revealed that the ARID5B SNPs associated with ALL in previous GWAS were also associated with AML and that, conversely, rs4132601 in IKZF1 also positively associated with ALL in the published GWAS was inversely related to AML. Both findings require replication. Abbreviations: A1, variant allele; A2, common allele taken as reference class in the model; AML, acute myeloblastic leukemia; CI, confidence interval; Co, controls; MAF, minor allele frequency; MAF AML , MAF in the cases; MAFco, MAF in ESCALE controls; OR A , allelic odds ratios for carriership of the allele A1 and 95% CI for comparison with ESCALE controls, estimated using a logistic regression model adjusting for age Â sex strata; OR G , genotypic odds ratios and 95% CI for comparison to ESCALE controls, estimated using a logistic model adjusting for age Â sex strata; ref., reference; SNP, single-nucleotide polymorphism. *0.01pPo0.05; **0.05pPo0.10; ***0.001pPo0.01.
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